Literature DB >> 29627432

Influence of Parkinsonism on outcomes of elderly pneumonia patients.

Taisuke Jo1, Hideo Yasunaga2, Nobuaki Michihata3, Yusuke Sasabuchi4, Wakae Hasegawa5, Hideyuki Takeshima5, Yukiyo Sakamoto5, Hiroki Matsui2, Kiyohide Fushimi6, Takahide Nagase5, Yasuhiro Yamauchi5.   

Abstract

INTRODUCTION: Pneumonia is one of the most frequent reasons for hospitalization in patients with Parkinson's disease. The present study aimed to evaluate the impact of Parkinsonism on the clinical courses of elderly patients hospitalized for pneumonia.
METHODS: We conducted a retrospective cohort study of patients aged ≥60 years who were hospitalized for pneumonia, using data from a national inpatient database in Japan. We performed one-to-four matching for age and sex between patients with and without Parkinsonism. Multivariable regression analyses were carried out for in-hospital mortality, length of stay, and discharge to home.
RESULTS: Patients with Parkinsonism had significantly lower in-hospital mortality than those without Parkinsonism (odds ratio, 0.81; 95% confidence interval, 0.74-0.89). Length of stay was 8.1% longer in patients with Parkinsonism. Patients with Parkinsonism were less likely to be discharged to home (odds ratio, 0.62; 95% confidence interval, 0.58-0.67).
CONCLUSION: Parkinsonism was not an independent predictor of in-hospital mortality, but was related to prolonged length of stay and discharge other than to home in patients with pneumonia.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mortality; Parkinsonian disorders; Patient discharge; Pneumonia; Retrospective studies

Mesh:

Year:  2018        PMID: 29627432     DOI: 10.1016/j.parkreldis.2018.03.028

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

1.  Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders.

Authors:  Stella M Papa; Patrik Brundin; Victor S C Fung; Un Jung Kang; David J Burn; Carlo Colosimo; Han-Lin Chiang; Roy N Alcalay; Claudia Trenkwalder
Journal:  Mov Disord       Date:  2020-04-16       Impact factor: 10.338

2.  Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders.

Authors:  Stella M Papa; Patrik Brundin; Victor S C Fung; Un Jung Kang; David J Burn; Carlo Colosimo; Han-Lin Chiang; Roy N Alcalay; Claudia Trenkwalder
Journal:  Mov Disord Clin Pract       Date:  2020-04-16

Review 3.  COVID-19 and Parkinson's Disease: Possible Links in Pathology and Therapeutics.

Authors:  Shubhangini Tiwari; Neelam Yadav; Sarika Singh
Journal:  Neurotox Res       Date:  2022-07-13       Impact factor: 3.978

4.  Comparison of the Effects of COVID-19 Pandemic on Male and Female Gender in Patients Diagnosed with Idiopathic Parkinson's Disease: A Case of Sakarya Province, Turkey.

Authors:  Yeşim Güzey Aras; Belma Doğan Güngen; Türkan Acar; Bilgehan A Acar; Sena Boncuk; Halil A Eryilmaz
Journal:  Noro Psikiyatr Ars       Date:  2022-08-19       Impact factor: 1.066

5.  Prevalence and outcomes of Covid-19 in Parkinson's disease: Acute settings and hospital.

Authors:  Conor Fearon; Alfonso Fasano
Journal:  Int Rev Neurobiol       Date:  2022-04-20       Impact factor: 4.280

6.  Hospital Magnet Status Associates With Inpatient Safety in Parkinson Disease.

Authors:  Whitley W Aamodt; Jasmine Travers; Dylan Thibault; Allison W Willis
Journal:  J Neurosci Nurs       Date:  2021-06-01       Impact factor: 1.627

7.  COVID-19 and the brain: impact on nuclear medicine in neurology.

Authors:  Silvia Morbelli; Ozgul Ekmekcioglu; Henryk Barthel; Nathalie L Albert; Ronald Boellaard; Diego Cecchin; Eric Guedj; Adriaan A Lammertsma; Ian Law; Ivan Penuelas; Franck Semah; Tatjana Traub-Weidinger; Elsmarieke van de Giessen; Andrea Varrone; Valentina Garibotto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10       Impact factor: 9.236

Review 8.  Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience.

Authors:  Alfonso Fasano; Angelo Antonini; Regina Katzenschlager; Paul Krack; Per Odin; Andrew H Evans; Thomas Foltynie; Jens Volkmann; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2020-05-04

Review 9.  COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

Authors:  Luigi Ferini-Strambi; Maria Salsone
Journal:  J Neurol       Date:  2020-07-21       Impact factor: 4.849

10.  The Possible Protective Role of α-Synuclein Against Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Patients With Parkinson's Disease.

Authors:  Sofiane Ait Wahmane; Abderrahmane Achbani; Zakaria Ouhaz; Mohamed Elatiqi; Ahmed Belmouden; Mohamed Nejmeddine
Journal:  Mov Disord       Date:  2020-07-16       Impact factor: 9.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.